The trial is single center, prospective study to collect coincident samples of oral fluid and blood to evaluate the time-course of glucose Trial is expected to enroll approximately 40 adult subjects diagnosed with type 2 diabetes GBS is seeking to support clinical validation of its Saliva Glucose

NEW YORK , March 07, 2022 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - - $11.19 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2021, Provides

Company to Host Conference Call & Webcast at 4:30 p.m. ET NEW YORK , Feb. 07, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it

NEW YORK , Dec. 20, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that Dr. Steven Boyages, GBS’ interim CEO and Chairman of the

NEW YORK , Dec. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that in collaboration with Life Science Biosensor Diagnostics Pty

NEW YORK , Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its rapid

 – Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test –  – Clinical Validation Study Results for SARS CoV2 Ab Test –  – Evaluating site locations for build out of high-tech manufacturing facility supported by $4.7 Million Grant Funding from Australian Government –  –

Company to Host Conference Call & Webcast at 4:30 p.m. ET NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it

NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced changes to its executive leadership team as the Company advances